Apr 15, 2021

Sunrise: the wearable sensor revolutionising sleep analysis

sleepdisorder
sleepapnoea
Sustainability
wearabletech
Leila Hawkins
4 min
Sunrise is enabling remote sleep monitoring at home to help diagnose sleep apnoea

It is estimated that sleep apnoea affects about 1 billion people worldwide, with some research suggesting it is experienced by over 50% of the population in some countries.

The condition is hard to diagnose, as sleep tests are complex and require overnight stays in labs and for the patient to be connected to devices via lots of wires. This is also the case with polysomnography, considered the gold standard for obstructive sleep apnoea diagnostics. It requires specialised personnel to prepare the patient, who is either hospitalised overnight, or sent home equipped with bulky equipment that often disrupts sleep. It is also time-consuming and complex to interpret the data, leading to delays in diagnosis.

Laurent Martinot and his brother Pierre founded Sunrise in 2015, with the aim of creating a simple way to analyse people's sleep behaviour. They were partly inspired by their father, an experienced respiratory physician and sleep specialist, and by their wish to grant everyone access to better sleep.

“Nowadays, anyone should be able to have easy and fast access to certified medical sleep tests for preventing serious health complications stemming from poor quality sleep” Laurent Martinot says.
 

Using AI to monitor sleep


Sunrise uses a new method of sleep monitoring through a novel biosignal via a wearable sensor placed on the chin. using artificial intelligence, it records jaw movements and matches them to sleep events. "Studies have shown that the chin is an excellent spot for studying our sleep at night. For the first time, all diagnostic information is available outside the hospital setting in normal sleeping conditions with a simple and comfortable test" the founders explains.

The three most common sleep disorders are insomnia, obstructive sleep apnoea (OSA), and restless leg syndrome. In the case of sleep apnoea, when breathing stops and starts during sleep, it remains undiagonised in up to 80% of cases.

"Patients affected by OSA live with consequences of poor sleep: daytime sleepiness, emotional stress, irritability and lack of concentration" the Martinot brothers tell us. "Additionally, OSA can lead to serious comorbidities, in particular cardiovascular diseases, depression, stroke, obesity, hypertension, diabetes and more. Clinical studies show that the death rate in patients with untreated OSA significantly increases over time."

Yet sleep is often neglected, despite being essential to good health. "Such disregard for our sleep health leads to negative consequences on life quality, productivity and increased public health costs. Some scientists even speak of an “epidemic” and point out the lack of public policies regarding the importance of sleep. Nevertheless, the economic and societal impact is enormous."
 

The cost of sleep disorders


They cite a report published by RAND Europe , showing the cost of insufficient sleep in 5 OECD countries: UK, USA, Canada, Japan and Germany. It presents troubling results showing that, due to poor sleep quality and insufficient sleep, up to $680 billion is lost annually across the five countries.

"Waiting lists in sleep laboratories can be months long in some countries. Furthermore, sleep physicians are often overloaded as their numbers are not suited to the prevalence of the disease. The demand for sleep studies and consequent treatment is greater than available health resources.

"There is an overall consensus within the medical community that more importance must be given to sleep health and the need for raising awareness in the general population."

The pandemic has also had an impact, with the closure of sleep laboratories and redeployment of respiratory healthcare staff to work on the frontline, leading to many patients requiring a sleep test to be placed on hold. Additionally, active COVID-19 patients seem to have higher rates of sleep problems.

"In a situation where hospitals and clinics must remain free for acute and urgent COVID-19 cases, it becomes extremely difficult to sort out those in critical need of sleep tests from the less severe cases. In such instances, an at-home and simple test such as Sunrise will allow to remotely diagnose those in need of treatment. Sunrise offers the possibility for doctors to continue their care of those more vulnerable to the disease."

Share article

Jul 28, 2021

5 mins with... Johannes Bhakdi, Quantgene

COVID19
Genomics
AI
biotechnology
3 min
5 mins with... Johannes Bhakdi, Quantgene
Johannes Bhakdi, CEO of Quantgene, tells us about their approach to identifying new COVID-19 variants

Quantgene is a US biotech company that uses AI and the cloud to do genomic testing. It was founded in 2015 to focus on cancer - integrating advanced genomics and molecular diagnostics systems with the cloud and AI systems. 

CEO Johannes Bhakdi tells us Quantgene is the first COVID-19 testing company to fully integrate variant identification - we find out more. 

Given the new Delta and Lambda variants, is the coronavirus mutating at a faster rate than most viruses?
 
The reason SARS-COV2 is mutating on a perceived higher rate is not that the individual viruses mutate at a higher rate, but that the base population infected with the virus is vastly higher. The absolute rate of global mutations is a direct function of how many people have the virus at any given point in time. Since this is a global pandemic, and tens of millions have been infected, we see more mutations. 

That makes it more unpredictable, because any single mutation that has an evolutionary advantage - like the Delta variant - can then take over and spread even faster.  

What is the usual process for testing and analysing viral mutations? 

The most effective tool for analysing mutations is Whole Viral Genome sequencing. It allows you to read out the entire genome of the virus. Once the wet-lab sequencing is complete, we use this information to map it against what is called a "reference genome", meaning the classic SARS-COV2 genome. This allows us to then see any differences between the investigated sample and the baseline genome of SARS COV2. 

We then use these differences to map them against a database of known mutations, like the Delta variant. That way we can see if we are dealing with any known variant, and if we have a new variant at our hands, as well as determine what this new variant does to the spike protein and how likely it is to be a problem with antigens and vaccines, based on the changed protein structure. This last step is not easy and not clear-cut, and there is some speculation into the determination of how problematic the mutated proteins are. 

 What does Quantgene do differently?  

At Quantgene, we are focusing on solving problems for our clients - may it be employers, movie productions or governments. That means we ensure that our client gets the COVID protection they need in the fastest possible time frame and at the highest precision possible - mostly at or below market prices. 

We are bringing together technologies like RT-PCR testing and mutation profiling/sequencing, as well as advanced bioinformatics and computational resources to ensure high-quality results are being delivered seamlessly. 

We are also adding important components such as real-time cloud software and medical services to it. Simply put, we turn the COVID problem into a one-click seamless solution that works better than others, so companies and government clients don't have to deal with laboratories, medical or software providers who point fingers at each other and fail to deliver in time and with high precision. COVID is too dangerous and important to risk falling short.     

Share article